Kymera Therapeutics (NASDAQ:KYMR) Director Sells $51,602,264.62 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 467,878 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director owned 472,267 shares in the company, valued at $52,086,327.43. This represents a 49.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 29th, Bruce Booth sold 45,367 shares of Kymera Therapeutics stock. The shares were sold at an average price of $107.06, for a total transaction of $4,856,991.02.
• On Monday, June 29th, Bruce Booth sold 31,283 shares of Kymera Therapeutics stock. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84.
• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total transaction of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.39, for a total transaction of $30,305,683.43.
• On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The stock was sold at an average price of $100.51, for a total transaction of $13,540,707.20.
• On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.98, for a total transaction of $140,771.84.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total transaction of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total transaction of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total transaction of $1,056,455.18.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $113.51 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The stock’s 50-day moving average is $86.87 and its two-hundred day moving average is $82.91. The firm has a market cap of $9.34 billion, a P/E ratio of -31.80 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.82) earnings per share. On average, equities analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on KYMR. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Truist Financial boosted their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday. Bank of America upped their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group raised their target price on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research note on Friday, June 26th. Finally, B. Riley Financial lifted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $121.41.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP lifted its stake in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in shares of Kymera Therapeutics during the third quarter valued at approximately $47,563,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.